What is HC Wainwright’s Forecast for WVE FY2027 Earnings?

WAVE Life Sciences Ltd. (NASDAQ:WVE) – HC Wainwright decreased their FY2027 earnings per share estimates for WAVE Life Sciences in a report released on Tuesday, April 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.90) per share for the year, down from their previous estimate of ($0.22). HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for WAVE Life Sciences’ FY2028 earnings at ($0.80) EPS, FY2029 earnings at ($0.59) EPS and FY2030 earnings at ($0.28) EPS.

Several other analysts have also recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Wednesday, January 21st. Bank of America dropped their price target on WAVE Life Sciences from $38.00 to $21.00 and set a “buy” rating for the company in a research report on Friday, March 27th. Wedbush boosted their price target on WAVE Life Sciences from $33.00 to $35.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Cantor Fitzgerald boosted their price target on WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, Canaccord Genuity Group boosted their price target on WAVE Life Sciences from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, WAVE Life Sciences currently has an average rating of “Moderate Buy” and an average target price of $30.63.

WAVE Life Sciences Stock Performance

Shares of WVE opened at $7.32 on Thursday. WAVE Life Sciences has a one year low of $5.02 and a one year high of $21.73. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -6.00 and a beta of -1.32. The stock has a 50 day moving average price of $11.20 and a 200 day moving average price of $11.22.

WAVE Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.02). WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%.The firm had revenue of $17.25 million for the quarter, compared to analysts’ expectations of $15.68 million.

Hedge Funds Weigh In On WAVE Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in WVE. CWM LLC boosted its stake in WAVE Life Sciences by 6,729.0% during the fourth quarter. CWM LLC now owns 2,117 shares of the company’s stock worth $36,000 after buying an additional 2,086 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in WAVE Life Sciences by 645.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock worth $38,000 after buying an additional 1,942 shares during the last quarter. Bessemer Group Inc. boosted its stake in WAVE Life Sciences by 1,156.3% during the third quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock worth $72,000 after buying an additional 9,135 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in WAVE Life Sciences by 1,441.6% during the third quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock worth $73,000 after buying an additional 9,284 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of WAVE Life Sciences by 44.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company’s stock valued at $76,000 after purchasing an additional 3,609 shares during the last quarter. Institutional investors and hedge funds own 89.73% of the company’s stock.

Insider Buying and Selling

In other WAVE Life Sciences news, CFO Kyle Moran sold 3,588 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $48,258.60. Following the transaction, the chief financial officer owned 134,385 shares of the company’s stock, valued at approximately $1,807,478.25. The trade was a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Chandra Vargeese sold 3,228 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $43,416.60. Following the transaction, the insider directly owned 408,246 shares in the company, valued at $5,490,908.70. This trade represents a 0.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 52,373 shares of company stock worth $757,527. 23.98% of the stock is currently owned by corporate insiders.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.